000162760 001__ 162760
000162760 005__ 20240320115514.0
000162760 0247_ $$2doi$$a10.1111/ene.15089
000162760 0247_ $$2pmid$$apmid:34472165
000162760 0247_ $$2ISSN$$a1351-5101
000162760 0247_ $$2ISSN$$a1468-1331
000162760 0247_ $$2ISSN$$a1471-0552
000162760 0247_ $$2altmetric$$aaltmetric:112843889
000162760 037__ $$aDZNE-2021-01416
000162760 041__ $$aEnglish
000162760 082__ $$a610
000162760 1001_ $$0P:(DE-2719)2811820$$aVöglein, Jonathan$$b0$$eFirst author
000162760 245__ $$aSeizure prevalence in neurodegenerative diseases-a study of autopsy proven cases.
000162760 260__ $$aOxford$$bBlackwell Science$$c2022
000162760 3367_ $$2DRIVER$$aarticle
000162760 3367_ $$2DataCite$$aOutput Types/Journal article
000162760 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655207986_925
000162760 3367_ $$2BibTeX$$aARTICLE
000162760 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000162760 3367_ $$00$$2EndNote$$aJournal Article
000162760 500__ $$aISSN 1468-1331 not unique: **2 hits**. (CC BY-NC)
000162760 520__ $$aKnowledge about the seizure prevalence in the whole symptomatic course, from disease onset to death, in neurodegenerative diseases (ND) is lacking. Therefore, the aim was to investigate seizure prevalence and associated clinical implications in neuropathologically diagnosed ND.Clinical records of cases from the Neurobiobank Munich, Germany, were analyzed. Neuropathological diagnoses of the assessed cases included Alzheimer disease (AD), corticobasal degeneration (CBD), frontotemporal lobar degeneration (FTLD), Lewy body disease (LBD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). Seizure prevalence during the whole symptomatic disease phase was assessed and compared amongst ND. Associations between first clinical symptom and seizure prevalence and between seizures and disease duration were examined.In all, 454 patients with neuropathologically diagnosed ND and with available and meaningful clinical records were investigated (AD, n = 144; LBD, n = 103; PSP, n = 93; FTLD, n = 53; MSA, n = 36; CBD, n = 25). Seizure prevalence was 31.3% for AD, 20.0% for CBD, 12.6% for LBD, 11.3% for FTLD, 8.3% for MSA and 7.5% for PSP. Seizure prevalence was significantly higher in AD compared to FTLD (p = 0.005), LBD (p = 0.001), MSA (p = 0.005) and PSP (p < 0.001). No other significant differences regarding seizure prevalence were found between the studied ND. Cognitive first symptoms in ND were associated with an increased seizure prevalence (21.1% vs. 11.0% in patients without cognitive first symptoms) and motor first symptoms with a decreased seizure prevalence (10.3% vs. 20.5% in patients without motor first symptoms). Seizures were associated with a longer disease duration in MSA (12.3 vs. 7.0 years in patients without seizures; p = 0.017).Seizures are a clinically relevant comorbidity in ND, particularly in AD. Knowledge of the first clinical symptom in ND may allow for estimation of seizure risk.
000162760 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000162760 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000162760 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x2
000162760 542__ $$2Crossref$$i2021-09-17$$uhttp://creativecommons.org/licenses/by-nc/4.0/
000162760 542__ $$2Crossref$$i2021-09-17$$uhttp://doi.wiley.com/10.1002/tdm_license_1.1
000162760 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000162760 650_7 $$2Other$$aAlzheimer disease
000162760 650_7 $$2Other$$aepilepsy
000162760 650_7 $$2Other$$aneurodegenerative diseases
000162760 650_7 $$2Other$$aseizure prevalence
000162760 650_7 $$2Other$$aseizures
000162760 650_2 $$2MeSH$$aAutopsy
000162760 650_2 $$2MeSH$$aHumans
000162760 650_2 $$2MeSH$$aMultiple System Atrophy: epidemiology
000162760 650_2 $$2MeSH$$aMultiple System Atrophy: pathology
000162760 650_2 $$2MeSH$$aPrevalence
000162760 650_2 $$2MeSH$$aSeizures: epidemiology
000162760 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: diagnosis
000162760 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: epidemiology
000162760 7001_ $$aKostova, Irena$$b1
000162760 7001_ $$0P:(DE-2719)2811333$$aArzberger, Thomas$$b2
000162760 7001_ $$aNoachtar, Soheyl$$b3
000162760 7001_ $$0P:(DE-2719)2811918$$aDieterich, Marianne$$b4
000162760 7001_ $$0P:(DE-2719)2810441$$aHerms, Jochen$$b5
000162760 7001_ $$aSchmitz, Peer$$b6
000162760 7001_ $$aRuf, Viktoria$$b7
000162760 7001_ $$0P:(DE-2719)2812263$$aWindl, Otto$$b8
000162760 7001_ $$aRoeber, Sigrun$$b9
000162760 7001_ $$0P:(DE-2719)2811642$$aSimons, Mikael$$b10
000162760 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b11
000162760 7001_ $$0P:(DE-2719)2810712$$aDanek, Adrian$$b12
000162760 7001_ $$0P:(DE-2719)9000906$$aGiese, Armin$$b13
000162760 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b14$$eLast author
000162760 77318 $$2Crossref$$3journal-article$$a10.1111/ene.15089$$bWiley$$d2021-09-17$$n1$$p12-18$$tEuropean Journal of Neurology$$v29$$x1351-5101$$y2021
000162760 773__ $$0PERI:(DE-600)2020241-6$$a10.1111/ene.15089$$gp. ene.15089$$n1$$p12-18$$tEuropean journal of neurology$$v29$$x1351-5101$$y2021
000162760 8564_ $$uhttps://onlinelibrary.wiley.com/doi/10.1111/ene.15089
000162760 8564_ $$uhttps://pub.dzne.de/record/162760/files/DZNE-2021-01416.pdf$$yOpenAccess
000162760 8564_ $$uhttps://pub.dzne.de/record/162760/files/DZNE-2021-01416.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000162760 909CO $$ooai:pub.dzne.de:162760$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000162760 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811820$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000162760 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811333$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000162760 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811918$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000162760 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810441$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000162760 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812263$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000162760 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811642$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000162760 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000162760 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810712$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000162760 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000906$$aExternal Institute$$b13$$kExtern
000162760 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000162760 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000162760 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000162760 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x2
000162760 9141_ $$y2022
000162760 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000162760 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-11
000162760 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-11
000162760 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NEUROL : 2021$$d2022-11-11
000162760 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000162760 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000162760 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000162760 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-11
000162760 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NEUROL : 2021$$d2022-11-11
000162760 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000162760 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-11
000162760 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000162760 9201_ $$0I:(DE-2719)1111016$$kClinical Dementia Research München$$lClinical Dementia Research München$$x0
000162760 9201_ $$0I:(DE-2719)1110002$$kAG Höglinger 1$$lTranslational Neurodegeneration$$x1
000162760 9201_ $$0I:(DE-2719)1140013$$kNeuropathology / Brainbank$$lNeuropathology / Brainbank$$x2
000162760 9201_ $$0I:(DE-2719)1111015$$kAG Höglinger 2$$lCoordinator of Clinical Parkinson Research$$x3
000162760 9201_ $$0I:(DE-2719)1110001$$kAG Herms$$lTranslational Brain Research$$x4
000162760 9201_ $$0I:(DE-2719)1210003$$kAG Neumann$$lMolecular Neuropathology of Neurodegenerative Diseases$$x5
000162760 9201_ $$0I:(DE-2719)1110008$$kAG Simons$$lMolecular Neurobiology$$x6
000162760 980__ $$ajournal
000162760 980__ $$aVDB
000162760 980__ $$aUNRESTRICTED
000162760 980__ $$aI:(DE-2719)1111016
000162760 980__ $$aI:(DE-2719)1110002
000162760 980__ $$aI:(DE-2719)1140013
000162760 980__ $$aI:(DE-2719)1111015
000162760 980__ $$aI:(DE-2719)1110001
000162760 980__ $$aI:(DE-2719)1210003
000162760 980__ $$aI:(DE-2719)1110008
000162760 9801_ $$aFullTexts
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1528-1157.1992.tb06222.x
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3233/JAD-170392
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.0b013e31828726f5
000162760 999C5 $$1Galvin E$$2Crossref$$oGalvin E 2019$$y2019
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.25945
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3109/09540261.2013.776523
000162760 999C5 $$1Togasaki DM$$2Crossref$$oTogasaki DM 2000$$y2000
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.49.5.1284
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.0000000000002638
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.20149
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S0140-6736(99)04137-9
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S0140-6736(00)82050-4
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/ene.14800
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s00401-008-0460-5
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1038/nrn2535
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s00401-011-0910-3
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.0000000000004058
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.jalz.2011.10.007
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/mds.26987
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.44.11.2015
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/01.wnl.0000324625.00404.15
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S1474-4422(09)70238-8
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s00401-007-0237-2
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.0b013e31827f0fd1
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1212/WNL.0b013e318204a36a
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.3233/JAD-170031
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1177/089198879400700407
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1080/13554790902971158
000162760 999C5 $$1Larner A$$2Crossref$$oLarner A 2010$$y2010
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.yebeh.2020.107311
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/ana.25157
000162760 999C5 $$1Beagle A$$2Crossref$$oBeagle A 2015$$y2015
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1001/archneur.1964.00460160003001
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/S0140-6736(18)32596-0
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s00415-020-09937-7
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1002/gps.930081106
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1159/000117218
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1007/s00415-020-09937-7
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/epi.12550
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1111/j.1528-1167.2008.01945.x
000162760 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.yebeh.2010.07.016
000162760 999C5 $$1Wilden JA$$2Crossref$$oWilden JA 2012$$y2012